Emtiaz Ahmed

Dr Emtiaz specializes in the development of nanotechnology-driven novel liquid biopsy platforms for the early-stage diagnosis of cancer and infectious diseases.

Dr Emtiaz Ahmed is currently a Postdoctoral Research Fellow at the Australian Institute for Bioengineering & Nanotechnology (AIBN), The University of Queensland (UQ), Australia. Prior to this role, he worked as a Research Officer at the International Centre for Diarrheal Disease Research, Bangladesh (icddr,b) for over five years, focusing on Infectious Disease Research. His work in icddr,b (https://www.icddrb.org/) cantered on studying various gastroenteric pathogens, including viruses, bacteria, and parasites. This involved investigating their incidence and role in gastroenteric diseases, identifying genotypes for vaccine development, studying host factors affecting infection susceptibility, and developing point-of-care diagnostic platforms. Dr Ahmed's exceptional achievements at icddr,b earned him the prestigious 'University of Queensland Research Training Program (UQ-RTP) Scholarship (2019-2023)' for his PhD studies at UQ, Australia. Dr Ahmed earned his doctoral degree in 2023 in Biomedical Engineering from the Australian Institute for Bioengineering & Nanotechnology (AIBN), the University of Queensland, receiving the Dean's award for an outstanding PhD thesis. He is a highly skilled biomedical researcher with a strong focus on the development of nanotechnology-based point-of-care technologies for early-stage cancer diagnosis and treatment monitoring. Dr Ahmed's skills not only benefit cancer and infectious disease diagnosis but also serve as valuable assets for clinicians in monitoring disease prognosis and selecting the most suitable treatments for individual patients, thereby improving treatment outcomes through precision medicine. Early in his scientific career, he has published 13 research articles in highly reputed international journals and garnered over 315 citations (with an h-index of 7), establishing a reputation for significant contributions to the fields of nanotechnologically engineered cancer diagnosis, treatment monitoring, infectious disease diagnosis, vaccine development, and public health research as on October 2024.

Dr Emtiaz has presented his developed biosensors for cancer diagnosis at two prestigious international conferences in South Korea—the Biosensor Conference 2021 and the World Congress on Biosensors 2023—showcasing excellence in Australian biomedical research. He has also presented his findings at two national conferences in Sydney, Australia: the Thomas Ashworth CTC & Liquid Biopsy Symposium 2021 and the Australian Society for Medical Research (ASMR) annual conference, engaging a diverse audience of global health researchers and policymakers. Additionally, Dr Emtiaz has served as a Casual Academic in the Department of Mechanical and Mining Engineering at the University of Queensland for three consecutive years, preparing Australia’s next generation of engineers. Over this period, he taught three cohorts of master’s students (each cohort comprising approximately 60 students), covering topics in nanotechnology and biomedical engineering. He also provided hands-on training in developing various miniaturized devices for a range of applications.